Ph.D., Founder and Chief Science Officer, Cognition Therapeutics Inc.
Biography
Dr. Catalano is a pharmaceutical executive with 22 years of experience in the strategic and operational scientific leadership. With training in neurobiology and oncology drug discovery and drug development, she has been a member of the board of directors since co-founding the company in 2007. Dr. Catalano guided the discovery and development of CT1812 and established the “International Symposium on Sigma-2 Receptors: Role in Health and Disease.” She has authored numerous publications and patents and continues to serve as principal investigator of several NIH awards. In addition, Dr. Catalano serves on various NIH review panels in the areas of drug discovery and clinical development in neurodegeneration. Previously, Dr. Catalano has held leadership positions at Acumen Pharmaceuticals, Inc., Rigel Pharmaceuticals, Inc., and Roche Biosciences. Dr. Catalano received a B.A. from Barnard College and a Ph.D. in Neurobiology from U.C. Irvine before postdoctoral training at U.C. Berkeley and Caltech.
